soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Updates in Medicine on X: "SOUL (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in Semaglutide cardiovascular outcomes align more

This guide is for educational and informational purposes only

It may also benefit individuals with obesity, prediabetes, type 2 diabetes, high blood pressure, PCOS, or other conditions that require careful medical monitoring during treatment

Importantly, many patients are exempt from prescription charges, including those with diabetes treated with any medication (not just insulin)

Many people taking Ozempic or other GLP-1 medications may not eat enough, and studies have found that their diets often lack important nutrients, including iron

Its essential to monitor any changes in the skins condition, including rashes, to ensure they are managed appropriately

Comparison of cystatin C and creatinine as predictors of cardiovascular events in a community-based elderly population